Humana Inc. (NYSE:HUM) saw a significant decline in short interest in August. As of August 31st, there was short interest totalling 2,679,854 shares, a decline of 36.0% from the August 15th total of 4,190,098 shares. Based on an average daily volume of 864,285 shares, the days-to-cover ratio is currently 3.1 days. Currently, 1.9% of the company’s stock are short sold.

In other Humana news, CEO Bruce D. Broussard sold 12,000 shares of the business’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $251.88, for a total transaction of $3,022,560.00. Following the transaction, the chief executive officer now owns 80,086 shares in the company, valued at $20,172,061.68. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Elizabeth D. Bierbower sold 9,786 shares of the business’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $259.00, for a total value of $2,534,574.00. Following the transaction, the insider now owns 18,042 shares in the company, valued at approximately $4,672,878. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,566 shares of company stock worth $15,326,746. 0.80% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in HUM. BlackRock Inc. lifted its stake in Humana by 2,281.7% during the first quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock worth $2,553,487,000 after purchasing an additional 11,867,056 shares during the period. FMR LLC lifted its stake in Humana by 57.9% during the first quarter. FMR LLC now owns 5,050,853 shares of the insurance provider’s stock worth $1,041,184,000 after purchasing an additional 1,851,197 shares during the period. Janus Henderson Group PLC lifted its stake in Humana by 7,848.8% during the second quarter. Janus Henderson Group PLC now owns 1,567,587 shares of the insurance provider’s stock worth $377,192,000 after purchasing an additional 1,547,866 shares during the period. Renaissance Technologies LLC lifted its stake in Humana by 84.3% during the first quarter. Renaissance Technologies LLC now owns 2,691,700 shares of the insurance provider’s stock worth $554,867,000 after purchasing an additional 1,231,400 shares during the period. Finally, Wellington Management Group LLP lifted its stake in Humana by 2,651.1% during the first quarter. Wellington Management Group LLP now owns 775,755 shares of the insurance provider’s stock worth $159,915,000 after purchasing an additional 747,557 shares during the period. Hedge funds and other institutional investors own 95.12% of the company’s stock.

Humana (NYSE:HUM) opened at 240.04 on Wednesday. Humana has a 12-month low of $163.50 and a 12-month high of $259.76. The company has a market capitalization of $34.69 billion, a price-to-earnings ratio of 19.75 and a beta of 0.87. The stock’s 50 day moving average price is $250.95 and its 200 day moving average price is $232.23.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, topping analysts’ consensus estimates of $3.08 by $0.41. The firm had revenue of $13.53 billion during the quarter, compared to analysts’ expectations of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same quarter last year, the company earned $2.30 earnings per share. On average, equities research analysts anticipate that Humana will post $11.55 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Tuesday, August 29th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend is Thursday, September 28th. Humana’s dividend payout ratio is 13.06%.

HUM has been the topic of several recent analyst reports. Zacks Investment Research cut Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Leerink Swann boosted their price target on Humana from $250.00 to $265.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 30th. Royal Bank of Canada reiterated a “hold” rating and issued a $214.00 price target on shares of Humana in a research note on Monday, June 5th. Morgan Stanley initiated coverage on Humana in a research note on Tuesday, June 6th. They issued an “overweight” rating and a $262.00 price target on the stock. Finally, Argus upgraded Humana from a “hold” rating to a “buy” rating and set a $260.00 price target on the stock in a research note on Friday, June 9th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the company’s stock. Humana presently has an average rating of “Buy” and a consensus price target of $244.35.

COPYRIGHT VIOLATION WARNING: “Humana Inc. (HUM) Short Interest Down 36.0% in August” was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.watchlistnews.com/humana-inc-hum-short-interest-down-36-0-in-august/1574379.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.